Last updated on October 2018

A Study of Brentuximab Vedotin + Adriamycin Vinblastine and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hodgkin's Disease
  • Age: Between 5 - 17 Years
  • Gender: Male or Female

Inclusion Criteria:

Each participant must meet all the following inclusion criteria to be enrolled in the

  1. Histologically confirmed CD30+ classical HL.
  2. Advanced stage, newly diagnosed HL (Stage III and Stage IV disease).
  3. Treatment-naive HL.
  4. Have performance scores of greater than or equal to (>=) 50 for Lansky Play-performance or Karnofsky Performance Status.

Exclusion Criteria:

  1. Nodular lymphocyte predominant HL.
  2. Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML.
  3. Any sensory or motor peripheral neuropathy.
  4. Symptomatic neurologic disease compromising normal activities of daily living or requiring medications.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.